 PARIS and CAMBRIDGE, Mass., Sept. 29, 2021 GLOBE NEWSWIRE -- Biophytis SA NasdaqCM: BPTS, Euronext Growth Paris: ALBPS, a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces it will present full results from the SARA-INT Phase 2 trial of Sarconeos BIO101 in Sarcopenia at the International Congress on Frailty and Sarcopenia Research ICFSR to be held virtually from September 29 to October 02, 2021. 